Risk management in the treatment of type 2 diabetes with pioglitazone by Derosa, Giuseppe & Salvadeo, Sibilla AT
© 2009 Derosa and Salvadeo, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 51–60
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
51
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
risk management in the treatment of type 2 
diabetes with pioglitazone
Giuseppe Derosa 
Sibilla AT Salvadeo
Department of internal Medicine  
and Therapeutics, University of Pavia, 
Pavia, italy
Correspondence: Giuseppe Derosa 
Department of internal Medicine and 
Therapeutics, University of Pavia, Pavia, italy 
email giuseppe.derosa@unipv.it
Introduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. 
Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese 
subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. 
Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic 
control and reducing cardiovascular morbidity and mortality.
Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone 
in the prevention and management of atherosclerosis in patients with type 2 diabetes.
Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, 
and particularly the recent evidence in the field of atherosclerosis and cardiovascular 
prevention.
Place in therapy: The current evidence shows that pioglitazone is an effective option in the 
treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in 
atherosclerosis prevention beyond glycemic control.
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Introduction
Around 246 million people are affected by type 2 diabetes, and this number is 
expected to be around 380 million by 2025.1 The associated annual mortality rate 
has been estimated to be around 5.5% of all patients.2 During the last decade, most 
of the commonly used drugs for diabetes have been shown to provide benefits on the 
cardiovascular (CV) system. Experimental evidence showed that metformin improves 
vascular function and procoagulant state by reducing circulating levels of plasminogen 
activator inhibitor-1.3,4
Data from UKPDS in 1998 suggested that metformin could be responsible of a 
significant reduction of diabetes-related death and acute myocardial infarction (AMI) 
in obese patients initially randomized to monotherapy.5 The mechanism of action 
and the real contribution of metformin in reducing CV mortality was not definitively 
assessed in this study. An observational study has recently showed that treatment 
with metformin is associated with a lower CVD-related mortality rate compared to 
sulfonylurea monotherapy.
Although microvascular complications can lead to significant morbidity and 
mortality, the greatest cause of death in patients with type 2 diabetes is CV disease.
Data obtained over the past decade have demonstrated that the risk of microvascular 
complications of type 1 and type 2 diabetes can be reduced by intensive glycemic 
control.5,6 According to results of two large clinical trials, the Diabetes control and Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 52
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Complications Trial (DCCT) and the UK Prospective 
Diabetes Study (UKPDS), the American Diabetes Asso-
ciation (ADA) recommends a glycosylated hemoglobin 
(HbA1c) value 7% for most subjects with diabetes mellitus, 
with more or less strict control in particular groups of patients 
and conditions (ie, pregnancy).
The relationships between strict glycemic control, 
represented by adequate values of glycosylated hemoglobin 
A1c(HbA1c), and CV disease are still less clearly defined, despite 
results of  DCCT and UKPDS. Recently published results of tree 
large clinical trials have further enriched the acknowledgement 
about a direct effect of tight glycemic control and reduction 
of CV disease in patients with type 2 diabetes. Two of  these 
studies, Action in Diabetes and Vascular Disease Preterax 
and Diamicron modified Release Controlled Evaluation 
(ADVANCE)7 and Veterans Affairs Diabetes Trial (VADT),8 
have shown that CV outcomes are not significantly reduced 
by strict glycemic control. On the other hand, a third trial, the 
action to Control Cardiovascular risk in Diabetes (ACCORD),9 
has been stopped earlier than expected due to a significant 
increase in mortality in participants randomized to very 
intensive glycemic control (HbA1c  6%). According to these 
findings, the ADA revised recommendations for glycemic 
targets in patients with diabetes mellitus.
A well thought out analysis of the studies published in 
2008 (ACCORD, STENO 2 post-trial, ADVANCE, VADT, 
UKPDS post-trial, Epidemiology of  Diabetes Interventions 
and Complications [EDIC]) highlighted the existence of 
glycemic memory, the non-existence of blood pressure 
memory, the need to control all CV risk factors and to 
treat diabetes mellitus early while avoiding hypoglycemic 
incidents. The glycemic target based on HbA1c must take 
into account the patient’s age and the duration of diabetes, 
as well as cardiovascular risk factors and previous glycemic 
control. All in all, the intensive treatment of type 2 diabetes 
must begin early; it must not be too rapid and must avoid 
hypoglycemic incidents and be combined with a strict control 
of other CV risk factors.10
In addition to lowering blood glucose levels and 
ameliorating lipids concentration, thiazolidinediones (TZDs) 
have anti-inflammatory and antithrombotic effects. In fact 
both pioglitazone and rosiglitazone have been shown to 
improve endothelial dysfunction.11
Recently, two large clinical trials, PROactive and PERI-
SCOPE, have provided data suggesting a role of pioglitazone 
in preventing CV events in patients with type 2 diabetes 
mellitus. Whether these effects translate into beneficial CV 
outcomes is still controversial and CV side effects, such 
as heart failure (HF), have been reported in clinical trials 
of TZDs.12,13
Rosiglitazone trials with CV outcomes are ongoing. Data 
from the RECORD (Rosiglitazone Evaluated for Cardiac 
Outcome and Regulation of  Glycemia in Diabetes) study 
have been recently published in an interim analysis and show 
no statistically significant difference between rosiglitazone 
and placebo in preventing AMI, death from CV causes or 
death from any other causes.14
In this manuscript we highlight the efficacy and safety of 
pioglitazone, a TZD, in improving a number of well estab-
lished and recently recognized CV risk factors which need 
to be addressed in diabetes mellitus management.
Efficacy studies with pioglitazone
A large number of data are available on the efficacy of 
pioglitazone in glycemic control. In a study involving 408 
patients with type 2 diabetes mellitus, who underwent 
discontinuation of previous therapy, pioglitazone significantly 
reduced HbA1c and fasting plasma insulin (FPI) after 
3 months, while reduction in fasting plasma glucose (FPG) 
was reached after a longer period.15 A post-hoc analysis 
of these results showed a significant increase in insulin-
sensitivity, expressed by Homeostasis Model Assessment 
index (HOMA index) (p  0.05 with 15 mg/day and 
p  0.001 with increased doses from 30 to 45 mg die).16
In studies with low doses of pioglitazone (15 or 
30 mg/day), the effects on HbA1c and FPG were comparable 
with the two dosages of administration. Moreover, both 
dosages required a 4-week period before their effects could 
be demonstrated. Even when pioglitazone, at doses ranging 
from 30 to 45 mg/day, was administered to patients with 
normal to moderate levels of HbA1c, HOMA index and FPG 
were significantly improved (p  0.001, for both parameters). 
In two large studies, pioglitazone induced a significant 
improvement of  high-density lipoprotein cholesterol (HDL-C) 
(p  0.001), without significant differences between different 
dosages, while high doses, 45 mg/day, were related to sig-
nificant reduction of triglycerides (Tg) and apolipoprotein 
B (Apo B) (p  0.01 and p  0.05). No low-density 
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lipoprotein (LDL-C) reduction was observed in either study, 
even though high-density lipoproteins/low-density lipopro-
teins (HDL/LDL) ratio was improved in one study.17,18
Pioglitazone, administered in monotherapy at dosage of 
30 mg/day, has been investigated in a large study including 
197 subjects with type 2 diabetes mellitus. Pioglitazone sig-
nificantly reduced FPG, HbA1c, C-peptide and FPI (p  0.05, 
for all comparisons). In conclusion, pioglitazone seemed to 
beneficially affect both glycemic control parameters and lipid 
profile in terms of reduction in Tg and increase in HDL-C, 
with small effects on LDL-C (Table 1).19
When pioglitazone is compared with metformin, it shows 
a similar effect in glycemic control. In one study, involving 
205 patients with type 2 diabetes, both pioglitazone and 
metformin reduced HbA1c (–1.3% and –1.5%, p  0.0001, 
respectively), FPG (–3.0 and –2.8 mmol/L, p  0.001, 
respectively) and FPI (–17.0%, p  0.01 vs baseline; –14.9% 
vs baseline, p  0.05, respectively) after 24 weeks. At the end 
of the study, pioglitazone showed a greater effect on reduc-
tion of FPI than metformin (p  0.05 for comparison).20
In another study, pioglitazone reduced FPG (–2.5 
vs –2.2 mmol/L, p  0.05, respectively) and Tg (–0.61 
vs –0.30 mmol/L, p  0.001, respectively) to a greater extent 
than metformin. Moreover, pioglitazone showed a major 
effect on HDL-C (0.16 vs 0.08 mmol/L; p  0.001), FFA 
(0.16 vs –0.08 mmol/L; p  0.001) and urinary albumin excre-
tion rate (AER) (–19.0% vs –1.0%, p  0.005, respectively).21
One of the main issues in type 2 diabetes management 
is preventing the progressive impairment of pancreatic 
β-cell function. Studies in vivo reveal that TZDs pro-
mote β-cell survival and regranulation as well as maintenance 
of β-cell mass and reduction of amyloid deposition. Recent 
data are available which support the notion that TZDs have 
beneficial effects on β-cell function. These clinical studies 
demonstrated that TZDs are able to prevent or delay the 
development of type 2 diabetes mellitus in a high-risk popu-
lation through restoration of the first-phase insulin response 
and improvement of secretory responses to oscillations in 
plasma glucose levels. Many of these effects appear to be 
independent of improvement in insulin sensitivity. Emerg-
ing evidence suggests that TZDs offer specific benefits for 
preventing or delaying the decline in β-cell function and, 
thereby, a substrate for early intervention efforts aimed at 
lowering the burden type 2 diabetes mellitus.22
Compared with sulfonylureas, pioglitazone produces a 
greater reduction of HbA1c, and improves insulin sensitivity. 
Compared with glibenclamide, pioglitazone increases insu-
lin sensitivity (HOMA index 13.0% vs 17.0 %, p  0.001, 
respectively) and β-cell function after 36 weeks. Results of 
comparator studies suggest that even if pioglitazone effects 
on HbA1c require a longer period to be evident, pioglitazone 
allows a more sustained glycemic control and improvement 
in insulin sensitivity than glibenclamide.23
Results from clinical studies clearly show a substantial 
superiority of pioglitazone in ameliorating lipids in diabetes 
patients, compared with other molecules. Pioglitazone 
significantly increases HDL-C while both glimepiride and 
glibenclamide do not affect this parameter. Compared with 
glibenclamide, pioglitazone significantly reduces Tg, but, 
compared with glimepiride, similar and non-significant 
effects on Tg have been observed for both drugs. Both 
pioglitazone and glibenclamide induce a moderate increase 
in LDL-C.24,25
For lipoprotein subfractions, pioglitazone increases the 
larger subfractions of LDL-C and HDL-C compared with 
metfomin and glibenclamide, and reduces small-dense 
LDL-C subfractions (sdLDL), which are ameliorated also 
by metformin.16
Some data suggest a superior effect of pioglitazone 
in association with metformin, compared with treatment 
with rosiglitazone and metformin. In a recent study, 
significant total cholesterol (TC), LDL-C, HDL-C, Tg, 
apolipoprotein AI (Apo AI), and Apo B were ameliorated 
in the pioglitazone group, but not in the rosiglitazone group, 
after 12 months. These variations were significant between 
groups (p  0.05).26
In our experience, an association of pioglitazone 
or rosiglitazone and glimepiride shows a greater effect 
of pioglitazone on lipid profile in patients with type 2 
diabetes no longer responding to glimepiride. In one study, 
pioglitazone in association with glimepiride significantly 
Table 1 Pioglitazone effects on lipoproteins
Site Effects
Blood  ↓ Tg 
↓ FFA 
↓ Lipid perox 
↓ TNF-α 
↓ resistin 
↓ sdLDL 
↑ HDL-C 
↑ LDL 1, HDL 2
Adipose tissue ↑ Transport proteins of FFA 
Liver  ↓ ApoCiii 
↑ ApoAi
Abbreviations: Tg, triglycerides; ApoCiii, apolipoprotein Ciii; FFA, free fatty acids; 
ApoAi, apolipoprotein Ai; sdLDL, small-dense LDL; HDL-C, high-density lipoprotein 
cholesterol;  LDL, low-density lipoprotein.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 54
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improved TC (–11.0%), LDL-C (–12.0%), HDL-C (15.0%) 
and Apo B (–10.6%) (p  0.05 for all parameters), compared 
with add-on therapy with rosiglitazone, which worsened the 
same parameters (Table 2).27
In a meta-analysis by Iki-Yarvinien, both pioglitazone and 
rosiglitazone increased HDL-C (10%) to a similar extent, but 
pioglitazone has shown a better effect on Tg (20%).28
Accumulating evidence clearly shows that TZDs affect 
CV risk factors. There is no clear statement about the real 
effects of TZD on the single recognized parameter that 
increases CV risk, while much evidence is available on the 
so-called ancillary effects of TZDs.
Pioglitazone seems to be as efficacious as rosiglitazone 
in reducing systolic blood pressure (SBP) and diastolic 
blood pressure (DBP). In a study on non-dipper subjects 
with type 2 diabetes mellitus, patients treated with metfor-
min and pioglitazone underwent a significant improvement 
of ambulatory BP monitoring after 8 weeks, not observed 
with metformin monotherapy and independent of changes 
in glycemic control.29
In another similar study, both pioglitazone and rosi-
glitazone in association with glimepiride and metformin 
significantly reduced SBP and DBP in 87 subjects with 
type 2 diabetes (p  0.05), independently of improvement 
in metabolic parameters.30
In a recent 12-month study, the combination of TZDs 
and metformin was found to be associated with a slight, 
but significant, improvement in the long-term BP control 
(p  0.05), related to a similar reduction in insulin resis-
tance. In association with metformin, both pioglitazone and 
rosiglitazone add-on therapy appear to significantly improve 
BP control.31
Available data suggest that pioglitazone is effective in 
reducing AER, both in monotherapy and in combination 
with metformin or sulfonylureas, as demonstrated in the 
large QUARTET study. Compared with metformin plus 
sulfonylureas, addition of pioglitazone to a sulfonylurea 
resulted in reduction of the AER, a small but significant rise 
in LDL-C, and significantly greater improvements of Tg and 
HDL-C levels.32
In another study, a combination of pioglitazone and met-
formin has been compared with a combination of gliclazide 
and metformin. Pioglitazone add-on therapy has been shown 
to be more effective than gliclazide in reducing AER.33
Emerging data suggest pioglitazone effectiveness in 
prevention and treatment of early organ damage.
Results from a comparative study have suggested that, 
despite similar improvements in metabolic control (HbA1c), 
a 24-week treatment with pioglitazone significantly improved 
intima-media thickness (-0.033 ± 0.052 mm; p  0.0001), 
pro-insulin intact concentration (-5.92 ± 10.04 pmol/L; 
p  0.0001), adiponectin (ADN) (10.9 ± 6.3 µg/mL; 
p  0.0001) and HOMA index (-2.21 ± 3.40; p  0.0001), 
compared with glimepiride. Reduction in intima-media thick-
ness has been correlated with improved insulin sensitivity 
(r = 0.29; p = 0.0003), and pro-insulin intact levels (r = 0.22; 
p = 0.006), while an inverse correlation has been found with 
ADN levels (r = -0.37; p  0.0001).34 Moreover, other data 
suggest that pioglitazone slows progression of intima-media 
thickness.35
Other studies are available about the effects of pioglitazone 
treatment on endothelium-dependent vasodilation. In a small 
study, pioglitazone did not decrease FPG and HbA1c in 
non-diabetes subjects but significantly improved endothelium-
dependent vasodilation measured by flow-mediated dilation 
(5.0% ± 2.2% to 6.3% ± 2.4%, p  0.05).36
In a small study involving patients with type 2 diabetes 
mellitus or impaired glucose tolerance (IGT) who were 
previously treated with percutaneous coronary intervention, 
pioglitazone significantly reduced coronary plaques volume 
after 6 months (101.3 ± 32.1 to 94.6 ± 33.6 mm3, -7.2%; 
p = 0.0023) and plasma Tg (–14.9%), while HDL-C was 
Table 2 Thiazolidinediones and lipid profile: experience of the authors
Treatment Results  Conclusions
Pioglitazone + glimepiride HbA1c  -1.3%**
TC  -3.76%*,†
LDL  -10.6%*,†
HDL  +9.5%*,†
Tg  -19.3%*,†
apoAi  +2.3%*
apoB  -9.0%*,†
Pioglitazone in association with glimepiride 
provided a significant improvement of lipid profile 
components; no changes were obtained for the same 
parameters with rosiglitazone (Derosa et al)27 
*p  0.05 vs baseline; **p  0.01 vs baseline; †p  0.05 vs the comparative treatment. 
Abbreviations: HbA1c, glycosylated hemoglobin;   TC, total cholesterol; LDL-C, low-density lipoprotein;  HDL-C, high-density lipoprotein;   Tg, triglycerides;  apoAi, apolipoprotein 
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substantially increased (+20.0%), without any significant 
change in LDL-C. Furthermore, high sensitivity C-reactive 
protein (hs-CRP) level decreased. 37
Significant effects of pioglitazone on non-conventional 
CV risk factors, such as lipoprotein (a) [Lp(a)] and homo-
cystein (HCT) have been recently demonstrated. In our 
experience significant Lp(a) and HCT improvement has been 
obtained after a 12-month treatment with pioglitazone com-
pared with baseline values, and Lp(a) change was significant, 
compared with the rosiglitazone group. Significant HCT 
decrease was observed in the rosiglitazone group at the end 
of the study. However, long-term treatment with metformin 
plus pioglitazone significantly reduced Lp(a) plasma levels, 
whereas metformin combined with rosiglitazone did not 
(Table 3).38
Results of two large clinical trials, the PROactive study 
and the PERISCOPE study, recently published, have clearly 
highlighted the role of pioglitazone in prevention of CV 
events.12,13
The PRO-active (PROspective pioglitAzone Clinical 
Trial in macroVascular events) has showed that treatment 
with pioglitazone is effective in improving a series of CV risk 
factors, resulting in a general reduction of CV morbidity and 
mortality. Tolerability of pioglitazone at different dosages 
(from 15 mg/day to 45 mg/day) has been evaluated, too. 
All patients enrolled presented macrovascular disease such 
as recent (6 months) AMI, acute coronary syndrome, 
re-vascularization, stroke, or severe peripheral arterial 
disease. The composite primary end-point was the time 
required for the presentation of a second CV event after 
randomization: death from all causes, non-fatal myocardial 
infarction (including silent AMI), stroke, acute coronary 
syndrome, coronary or peripheral revascularization, and 
amputation. Secondary end-points were the time preceding 
the first all-cause death, AMI (excluding silent AMI) and 
stroke (main secondary end-point). The primary end-
point was reduced by 10% by pioglitazone (15 to 45 mg) 
(pioglitazone 514/2605 events vs placebo 572/2633, hazard 
ratio [HR] 0.90 95% confidence interval [CI] 0.80–1.02; 
p = 0.095). When the first end-point is given only from 
clinical objectives, it was significant for pioglitazone by 16% 
for the pioglitazone group vs placebo (p = 0.027). Including 
re-vascularization events in the primary composite end-point 
actually reduces the significance of the results since revas-
cularization depends on the different possibility of different 
centers to conduct this surgical therapy. In conclusion, 
PROactive showed a substantial constant reduction of AMI, 
stroke, acute coronary syndrome, and cardiac re-vascular-
ization in patients treated with pioglitazone compared with 
placebo, and represents the first clinical trial that demon-
strated a possible reduction of CV morbidity and mortality 
in patients with type 2 diabetes.12
PERISCOPE (Pioglitazone Effect on Regression of 
Intravascular Sonographic Coronary Obstruction Prospective 
Evaluation) is a randomized, double-blind, multi-center 
study, whose results have been recently published, which 
involved 543 subjects with coronary disease and type 2 
diabetes mellitus. The main outcome was the ultrasonographic 
measure of percentage atheroma value (PAV) before and 
after 18 months’ treatment with glimepiride (1–4 mg/day) 
or pioglitazone (15–45 mg/day). At the end of the study, the 
mean PAV had been reduced by 16% in the pioglitazone group 
and increased of 0.73% by the glimepiride group (p = 0.002). 
Pioglitazone significantly reduced HbA1c, to a major extent, 
Table 3 Thiazolidinediones and non-conventional cardiovascular risk factors: experience of the authors
Treatment Results  Conclusions
Pioglitazone + metformin HbA1c  -1.0%**
TC  -6.4%*,†
LDL  -5.2%*,†
HDL  +4.34%*,†
Tg  -19.2%*,†
Lp (a)  -10.4%*,†
HCT  -17.3%*
Pioglitazone in association with metformin 
provided a significant improvement in Lp(a) 
concentration (Derosa et al)38
Pioglitazone + glimepiride HbA1c  -1.1%**
Tg  -19.0%*,†
PAi-i  -18.0%*
t-PA  -16.8%
Fg  -3.6%
Combination treatment produced a slight but 
significant reduction of PAI-I concentration 
(Derosa et al)30
*p  0.05 vs baseline; **p  0.01 vs baseline; †p  0.05 vs the comparative treatment.
Abbreviations: HbA1c, glycosylated hemoglobin;  TC, total cholesterol; LDL-C, low-density lipoprotein;  HDL-C, high-density lipoprotein;   Tg, triglycerides;  Lp(a), lipoprotein(a); 
HCT, homocysteine; PAI-1, plasminogen activator inhibitor 1; t-PA, tissue-plasminogen activator; Fg, fibrinogen.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 56
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compared with glimepiride (-0.55% vs 0.36%; respectively, 
p = 0.03 between groups), and increased HDL-C (+16% vs 
4.1 %) and Tg median value (-15.3% vs 0.6%) (p  0.001 
for both parameters). PERISCOPE is the first study to dem-
onstrate that pioglitazone can reduce coronary atheroma. As 
a great percentage (90%) of patients involved in this study 
was treated with an optimal therapy for glycemic and dyslip-
idemia control, pioglitazone has been shown to be able to add 
benefit to the recommended therapy. The authors concluded 
that there are many explanations for the mechanisms that 
lead to such encouraging results. PERISCOPE investigators 
have reported adverse events, even if clinical outcomes were 
not pre-specified in the study. In particular, edema and bone 
fractures (3.0%) were more frequent in patients treated with 
pioglitazone. Increases in body weight were observed in both 
groups, but differences were not significant.13
Safety and tolerability
Edema represents one of the most common and undesirable 
side effects of treatment with a TZD. Edema seems more 
common when TZDs are used in combination therapy. In the 
Matthew study, the incidence of edema in patients treated 
with pioglitazone and metformin was 6.3% and 2.2% in 
patients treated with gliclazide and metformin.33 Accumulat-
ing data support an increased risk of edema in patients treated 
with pioglitazone. In a study by Einhorn et al the incidence 
of peripheral edema increased by 5.9% in the group treated 
with pioglitazone and metformin compared with the group 
treated with metformin alone, even if the events in this study 
were described as mild to moderate.39 Fluid retention with 
TZDs may be considered a multi-factorial process. Excluding 
association with insulin, among combination treatments, the 
major incidence of edema has been reported when piogli-
tazone or rosiglitazone are associated with sulfonylureas.40
There are data supporting an increased risk of HF with 
pioglitazone. Both pioglitazone and rosiglitazone cause 
fluid retention and potentially promote congestive heart 
failure (CHF).
The mechanisms underlying this phenomenon have 
not been yet clearly described, even if some hypotheses 
have been proposed. Among these, the most studied are the 
increased expression of vascular endothelial growth factor, 
which simulates endothelial permeability,41 and the possible 
inhibition of A and B type natriuretic peptides, demonstrated 
in an in vitro model.42 In a recent study, echocardiographic 
parameters were not altered in patients treated for 3 months 
with pioglitazone 30 mg/day who have undergone an increase 
in N-terminal pro-B-type natriuretic peptide (NT-proBNP). 
In particular, no functional impairment has been observed 
in patients with basal high NT-proBNP.43
Analysis of recent data shows that treatment of type 2 
diabetes mellitus with a TZD increases signs of CHF, but not 
the risk of CV and overall death, and type 2 diabetics with pre-
existing HF benefit from a reduction in CV end-points.44
Results on the effects of TZDs on bone in humans are 
contrasting and few. Data available suggest that treatment 
with TZDs, primarily rosiglitazone, contributes to bone loss. 
The effect appears to be most prominent in post-menopausal 
women. More studies are needed to better understand the 
effects of TZDs on bone and fracture rates. As with all TZDs, 
pioglitazone increases the risk of osteoporosis. The mecha-
nisms by which pioglitazone reduces bone mass density have 
not been yet elucidated, even if recent data show that TZDs 
can influence differentiation of osteobasts.45 Few studies have 
evaluated differential effects of pioglitazone, rosiglitazone 
and troglitazone on bone loss. In a recently published study, 
hip body mass index (BMD) was measured by dual-energy 
X-ray absorptiometry in patients with type 2 diabetes treated 
with troglitazone, pioglitazone and rosiglitazone. Each year 
of treatment with TZD was associated with greater bone loss 
of the whole body in women but not in men. No data were 
provided about a possible differential effect of each TZD 
on bone loss, although this possibility has been suggested 
in other studies with TZD.46,47
Recently, TZDs have been evaluated in studies of treat-
ment of polycystic ovary syndrome (PCOS). In one study, 
pioglitazone treatment was followed by a significant decrease 
of hip and lumbar BMD and parameters of bone turnover in 
premenopausal women with PCOS, who are considered pro-
tected against bone loss by hyperinsulinemia. The mechanism 
of bone mineral loss in this and other studies has not been 
yet clarified and long-term intervention studies are required 
to elucidate the possible effects of pioglitazone on bone 
structure and turnover.48
No studies have directly evaluated differences in 
pioglitazone tolerability between human males and females. 
Recently the hypothesis that some adverse effects of TZDs 
could be related to specific interactions between these mol-
ecules and sex steroids has been proposed. Pioglitazone and 
rosiglitazone have been suggested to reduce testosterone 
biosynthesis and function. This hypothesis starts from the 
evidence of a possible link between low levels of testosterone 
and development of type 2 diabetes mellitus. An augmented 
incidence of side effects with pioglitazone and rosiglitazone 
may be further explained by a possible down-regulation of 
androgen biosynthesis.49 In a randomized controlled study, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 57
Pioglitazone and cardiovascular risk in type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
38 men with moderate to severe erectile dysfunction 
with poor response to sildenafil were pre-medicated with 
pioglitazone or placebo. Pioglitazone significantly improved 
major outcome measures, without affecting testosterone and 
dehydroepiandrosterone levels. Stronger conclusions about 
the interaction between pioglitazone and hormones would 
be obtained by investigating the effects of pioglitazone on 
sex steroids in larger randomized clinical trials.50
Aminotransferase increase represents another com-
mon problem that could be related to use of TZDs. In a 3-
year, randomized, double-blind safety study the incidence 
of alanine aminotransferase (ALT) elevation 3 times 
the upper limit during treatment with pioglitazone and 
metformin was comparable to that with glibenclamide and 
metformin. In the same study, the incidence of ALT and 
gamma-glutamyl-transpeptidase (γ-GT) 1.5 the upper 
limit and/or baseline was significantly more frequent with 
glibenclamide than with pioglitazone in association with 
metformin. Aspartate aminotransferase (AST) elevation was 
more frequent with pioglitazone but the mean changes in 
AST and ALT concentrations were lower in the pioglitazone 
group.51
According to results of clinical trials, hypoglycemia 
is less frequent with pioglitazone in combination with 
metformin than with the combination of sulfonylureas 
and metformin. These data have been confirmed in short- 
and long-term studies that have compared pioglitazone in 
association with metformin with the different sulfonylureas 
glimepiride,52 gliclazide,53 and glibenclamide54 administered 
with metformin.
Data are available that show an association between 
pioglitazone treatment and moderate reduction of  hematocrit 
and hemoglobin. No evidence exists to show a role of pio-
glitazone in determining anemia.55
A moderate body weight gain is well known in patients 
treated with TZDs, due to the stimulation of pre-adipocytes 
differentiation. In clinical studies, treatment with pioglitazone 
is often associated with moderate increase in body weight in 
a dose-dependent manner. Body weight increases during the 
period of treatment with pioglitazone are principally due to 
an increase in subcutaneous fat.56
Combination of pioglitazone with sulfonylureas 
magnifies the increase in body weight, while combination 
with metformin seems to moderate this effect. In a 12-month 
comparator study between pioglitazone and rosiglitazone 
combined with metformin, no body mass index (BMI) 
changes were observed in either group.26 Combination 
with pioglitazone showed a small increase in body weight 
compared with metformin alone, which slightly improved 
body weight (+0.95 kg vs -1.36 kg after 16 weeks).12 In other 
studies, combination treatment of pioglitazone and metformin 
has been associated with weight gain, comparable to body 
weight increase obtained with a combination of metformin 
and gliclazide (+1.5 vs 1.4 kg when compared to gliclazide 
after 52 weeks)33 and glimepiride (+1.74 vs 1.85 kg, after 
28 weeks).52
Finally, a recently published study of the combination 
of pioglitazone and sibutramine in type 2 diabetes patients 
intolerant to metformin and treated with sibutramine has 
shown a substantial equivalence in efficacy and tolerability 
between the two combination treatments. No changes in BMI 
and waist circumference were observed in patients treated 
with pioglitazone plus sibutramine. Results of this study 
suggest that a combination of pioglitazone with sibutramine 
might be a useful tool in obese patients with type 2 diabetes 
intolerant to metformin.57
Conclusions and place in therapy
TZDs represent one of the most promising tools in pharma-
cotherapy of type 2 diabetes.
As previously reported, in clinical studies pioglitazone 
has demonstrated efficacy in achieving glycemic control 
and amelioration of lipid profile. Moreover, improvement 
in insulin sensitivity is associated with a series of benefits in 
pro-inflammatory and atherogenetic features in patients with 
type 2 diabetes mellitus. However, many of the so-called 
ancillary, antiatherogenetic actions of pioglitazone are still 
not completely clear and more studies are needed to define 
the role of pioglitazone in prevention and care of organ 
damage, endothelial dysfunction, hypertension and cytokines 
profile. Side effects of treatment with pioglitazone appear 
moderate and very few subjects have dropped out of clinical 
trials because of adverse reactions, and adherence to correct 
prescription of the drug reduces the incidence of intolerance 
and patient risks. A good clinical evaluation at the beginning 
of treatment, if monitoring is adequate, enables safer adminis-
tration of pioglitazone and better results in clinical care. In the 
past 2 years, published reviews have stimulated debate on the 
open question of the risk of AMI with TZDs. We consider this 
issue in this paper as it has raised interesting discussions about 
pioglitazone safety and efficacy in patients at high CV risk.
A recent meta-analysis of 42 randomized control trials 
among 28,443 patients treated with rosiglitazone has shown 
an increase in the risk of AMI in treated subjects compared 
with controls (odds ratio 1.43; 95% CI 1.03–1.98; p = 0.03).58 
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trials with a specific intention of evaluating CV events in 
diabetes and non-diabetes subjects (pre-diabetes). Studies 
included had almost a 12-month follow-up period and 
provided numerical data of CV side effects. Results of this 
analysis, according to Nissen et al, have shown that rosigli-
tazone increases the risk of AMI (relative risk [RR] 1.42%; 
CI 95% 1.06–1.91; p = 0.02) and congestive HF (RR 2.09; 
CI 95% 1.52–2.88; p  0.001) without raising the risk of CV 
mortality (RR 0.90; CI 95% 0.63–1.26; p = 0.53). Limitations 
of collecting data from the studies included in the meta-
analysis and the limitations of a meta-analysis itself have 
been analyzed.59 After having considered these data, rosi-
glitazone label was modified by the FDA in August 2007.60
Data from PRO-active support a favorable impact of this 
molecule on CV risk. In particular, long- term treatment with 
pioglitazone seems to reduce the risk of AMI. A recent meta-
analysis investigated the effect of pioglitazone on CV events. 
The studies included (n = 19) in this analysis were random-
ized clinical trials, double-blind, controlled with placebo 
or active comparator. The primary outcome measure was a 
composite of death, AMI or stroke, and secondary end-point 
measures included the incidence of serious HF. Death, AMI 
or stroke occurred in 4.4% of patients receiving pioglitazone 
vs 5.7% patients receiving control drugs (HR 0.82; CI 95% 
0.72–0.94; p = 0.005), with a similar degree of reduction in 
every component of the primary end-point (HR 0.80–0.92), 
while serious HF was registered in 2.3% of the patients 
treated with pioglitazone vs 1.8% of patients treated with con-
trol drug therapy (HR 1.41 CI 95% 1.14–176; p = 0.002). In 
conclusion, pioglitazone appears related to a reduced risk of 
death, AMI or stroke among a diverse population of patients 
with type 2 diabetes mellitus. The risk of HF seemed to be 
higher with pioglitazone, without effects on mortality from 
HF.61 Recently published results from PERISCOPE should 
encourage physicians to consider pioglitazone as a molecule 
that substantially improves CV risk factors, even if other 
studies are required to better establish the pharmacological 
mechanisms underling these results and to define a precise 
role of pioglitazone in prevention of CV events.
Current treatment with pioglitazone in clinical practice 
has not been excluded by current guidelines, although 
more care is required in patients at risk of HF or AMI and 
in women with osteoporosis or at risk of bone fractures. 
Pioglitazone represents a valid tool in pharmacotherapy 
in patients characterized by insulin resistance such as 
obese subjects. No data are available that strongly sug-
gest a superiority of pioglitazone in lipids management 
in clinical practice; the evidence of a better impact of this 
molecule on lipids profile should be considered in clinical 
practice. For a reduction in intima-media thickness, no 
strong evidence exists for physicians to prefer pioglitazone 
rather than rosiglitazone. Pioglitazone appears to be well 
tolerated in association with metformin and sulfonylureas. 
In particular, in obese patients, the increase in body weight 
with pioglitazone can be partially reduced in combination 
with metformin. When pioglitazone is administered to the 
elderly, a very low incidence of hypoglycemia, the most 
dangerous side effect in these patients, was observed with 
monotherapy and when pioglitazone was combined with 
sulfonylureas, metformin or insulin.62 Few data are avail-
able about combination with TZDs and DPP-4 inhibitors 
and/or incretin mimetics. Preliminary conclusions presented 
in late 2008 at the European Association for the Study of 
Diabetes in Rome (Italy) suggest a favorable effect of these 
combinations on glycemic control with a moderate increase 
in body weight after 52 weeks.63 No data are available on the 
combination of exenatide and pioglitazone. More studies are 
needed in order to better understand the potential role and 
safety of these new drugs in association with pioglitazone 
in the prevention of atherosclerosis.
Patient perspectives
Pioglitazone is available in tablets (15, 30, 45 mg) and 
is usually administered independently of food, one or 
two times per day. This prescription provides good 
acceptability for patients with type 2 diabetes mellitus, 
who are commonly treated with a large number of drugs. 
As pioglitazone is approved in triple therapy, with met-
formin and sulfonylureas, many patients can undergo a 
delay in starting insulin treatment, as pioglitazone therapy 
is suggested to reduce HbA1c when combination therapy 
with metformin and sulfonylureas is not able to maintain 
glycemic control over time. Furthermore, pioglitazone 
preserves glycemic control over long periods. A common 
problem with pioglitazone is weight gain, even if it is com-
monly mitigated by combination with metformin or other 
therapies and adequate dietary advice.
Pioglitazone falls in the recommended cost-effective range. 
In a recent analysis, the addition of pioglitazone to existing 
therapy in high-risk patients with type 2 diabetes was projected 
to improve life expectancy, quality-adjusted life expectancy 
and complication rates compared with placebo.64
Recently, a fixed dose combination treatment of 
pioglitazone/metformin/pioglitazone/glimepiride has been 
approved and introduced on the market. Combination 
therapy is recommended as first-line treatment in obese Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 59
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patients with insulin resistance. The tolerability of a fixed 
dose seems comparable to the combination of pioglitazone 
and metformin, and appears well accepted by patients. More-
over, as effects of pioglitazone are usually delayed, fixed 
dose combination therapy hinders achievement of earlier 
glycemic control, rather than addition therapy.
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